Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Pudendal Nerve Block Techniques for Pain Control After Hemorrhoidectomy (PINPOINT)

7 settembre 2026 aggiornato da: Vinmec Healthcare System

Transgluteal Versus Transperineal Pudendal Nerve Block for Analgesia After Hemorrhoidectomy: A Randomized Superiority Trial (The PINPOINT Trial)

Hemorrhoidectomy is frequently associated with severe postoperative pain despite multimodal analgesia. Ultrasound-guided pudendal nerve block has become an effective regional analgesic technique, but it remains unknown whether blockade performed proximally at the ischial spine provides superior analgesia compared with the more distal transperineal approach.

The PINPOINT Trial is a prospective randomized assessor-blinded superiority trial comparing ultrasound-guided transgluteal (proximal) and transperineal (distal) pudendal nerve block in adults undergoing elective hemorrhoidectomy. The primary objective is to determine whether the proximal approach reduces cumulative opioid consumption during the first 48 postoperative hours. Secondary outcomes include pain intensity, opioid-related outcomes, recovery, complications, and patient-reported outcomes.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Context, rationale and hypothesis: Hemorrhoidectomy remains one of the most painful ambulatory surgical procedures, frequently associated with substantial postoperative opioid consumption despite multimodal analgesia. This persistent nociceptive burden has direct implications for delayed recovery, unplanned admissions, and opioid-related adverse events. Consequently, optimizing regional analgesic strategies is a priority within enhanced recovery pathways.

Pudendal nerve block (PNB), targeting sacral roots S2-S4, has emerged as an effective adjunct for postoperative analgesia in anorectal surgery. Randomized trials and meta-analyses consistently demonstrate reductions in pain scores and opioid requirements when PNB is incorporated into perioperative care. However, these studies encompass heterogeneous techniques, and critically, do not address whether the anatomical level of blockade influences clinical efficacy.

From a mechanistic perspective, the pudendal nerve divides into its terminal branches-the inferior rectal, perineal, and dorsal genital nerves-after traversing the region of the ischial spine and entering Alcock's canal. The inferior rectal nerve, which provides the principal sensory innervation to the anal canal and perianal region, typically branches proximally before the pudendal nerve courses distally within the pudendal canal. This anatomical arrangement suggests that distal approaches to PNB, such as the transperineal technique, may incompletely anesthetize the inferior rectal nerve due to injection beyond the point of branching or variable spread within the ischiorectal fossa.

In contrast, the posterior transgluteal approach targets the pudendal nerve at a more proximal location, near the ischial spine and sacrospinous ligament, where the nerve remains a single trunk. Ultrasound guidance at this level enables precise deposition of local anesthetic before division into terminal branches, theoretically ensuring a more consistent and comprehensive blockade, including the inferior rectal nerve. This distinction in injection level-proximal versus distal-represents a fundamental but underexplored determinant of block success.

Despite increasing adoption of ultrasound-guided regional anesthesia, there is a striking absence of randomized controlled trials directly comparing proximal (transgluteal) and distal (transperineal) approaches to PNB in the context of hemorrhoidectomy. Existing evidence is therefore insufficient to determine whether improved anatomical coverage translates into superior clinical analgesia or reduced opioid consumption.

Addressing this gap is clinically relevant for several reasons. First, inadequate blockade of the inferior rectal nerve may contribute to residual pain during defecation, a key determinant of patient dissatisfaction after hemorrhoidectomy. Second, identifying a more reliable and reproducible technique could standardize PNB within perioperative protocols. Third, demonstrating superiority of a proximal approach would support broader integration of ultrasound-guided regional techniques into opioid-sparing strategies.

The present trial is designed to test the hypothesis that a proximal, ultrasound-guided transgluteal PNB provides superior postoperative analgesia compared with a distal transperineal approach. By directly comparing these techniques in a randomized controlled setting, this study seeks to determine whether anatomical optimization of nerve blockade translates into meaningful clinical benefit.

Originality and innovative aspects: Hemorrhoidectomy remains associated with significant postoperative pain, often requiring substantial opioid consumption. Pudendal nerve block (PNB), targeting nerve roots from S2-S4, has demonstrated efficacy in reducing postoperative pain and opioid requirements. Anatomically, the pudendal nerve gives rise to the inferior rectal, perineal, and dorsal genital nerves. The effectiveness of PNB depends on the level of injection:

  • Transgluteal (proximal) approach: blockade at the level of the ischial spine before nerve branching
  • Transperineal (distal) approach: injection within or near Alcock's canal after branching The distal approach may spare the inferior rectal nerve, leading to suboptimal anorectal analgesia. In contrast, the proximal ultrasound-guided technique may provide a more complete and reliable block.

To date, no randomized controlled trial has directly compared proximal (transgluteal) and distal (transperineal) approaches to pudendal nerve block in hemorrhoidectomy, despite clear anatomical rationale suggesting differences in nerve coverage and analgesic efficacy.

Methods This study is a prospective, Randomized, Controlled, Parallel-group , Superiority trial, Assessor-blinded The protocol follows SPIRIT recommendations, and reporting will adhere to CONSORT guidelines Setting The study will be conducted at VinMec International Hospital, Can THo, Vietnam. Interventions Control Group (Standard Management): Trans perineal Group (Distal PNB) Spinal anesthesia protocol standardized; Ultrasound-guided transperineal approach ; Injection in rectoperineal/ischiorectal fossa; Bilateral; Ropivacaine 0. 5%, 8 mL per side; Oral Paracetamol 500 mg every 6 hours; Oral Celecoxib 200 mg every 12 hours ( if no contra-indication); Rescue opioids if NRS pain values >3/10 converted to MME Intervention Group: Transgluteal Group (Proximal PNB) General anesthesia protocol standardized; Ultrasound-guided posterior approach; Injection near ischial spine/sacrospinous ligament; Bilateral; Ropivacaine 0. 5%, 6 mL per side; Oral Paracetamol 500 mg every 6 hours; Oral Celecoxib 200 mg every 12 hours (if no contra-indication); Rescue opioids if NRS pain values >3/10 converted to MME

The Block Techniques:

Transperineal Approach Patient Positioning The patient is placed in the lithotomy position with slight hip abduction. Adequate exposure of the perineum is ensured under strict aseptic conditions.

Ultrasound Equipment and Probe Position A high-frequency linear transducer (10-18 MHz) is used. The probe is placed: Transversely or slightly oblique; On the perineum, lateral to the external anal sphincter; Over the ischio-rectal fossa.

Sonoanatomy Key structures to identify include: External anal sphincter (medial landmark); Ischioanal (ischiorectal) fossa (hypoechoic fat-filled space); Obturator internus muscle (lateral boundary); Internal pudendal artery (identified using color Doppler). The pudendal nerve is often not directly visualized, but lies medial to the internal pudendal artery and within or near Alcock's (pudendal) canal Needle Insertion Approach: in-plane, typically medial to lateral; Needle: 50mm echogenic needle advanced to the ischioanal fossa, adjacent to the internal pudendal artery.

Injection 8 mL of local anesthetic is injected per side. The spread should be observed within the ischioanal fossa Controlled by Color echo Doppler to prevent IV injection.

Transgluteal Approach Patient Positioning The patient is placed in the prone position (or lateral decubitus if needed). The gluteal region is exposed and prepared under sterile conditions.

Ultrasound Equipment and Probe Position A low-frequency curvilinear probe (2-5 MHz) or a high-frequency probe in lean patients may be used.

The probe is positioned transversely over the gluteal region, at the level of the ischial spine Sonoanatomy Key landmarks: Ischial spine (hyperechoic bony structure with acoustic shadow); Sacrospinous ligament; Sacrotuberous ligament; Internal pudendal artery (identified with Doppler). The pudendal nerve is located medial and posterior to the internal pudendal artery between the sacrospinous and sacrotuberous ligaments. It may appear as a small hyperechoic oval structure, although visualization is variable.

Needle Insertion Approach: in-plane, usually lateral-to-medial; Needle: 50 or 80 mm echogenic needle. The needle is advanced through the gluteal muscles, toward the ischial spine region, Into the interligamentous plane (between sacrospinous and sacrotuberous ligaments) Injection 6 mL of local anesthetic is injected per side. The spread of LA expands of the interligamentous space, circumferential spread around the pudendal artery controlled by Color echo doppler Sample Size: Assuming a mean 48h opioid consumption at 60 mg MME with a standard deviation: 30 mg and a clinically meaningful difference of 15 mg (25% reduction) with an Alpha risk : 0.05 (two-sided) and a β risk Power: 80%, the required sample is 64 patients per group. Accounting for 10% dropout the Total sample size: 140 patients (70 per group).

Analysis of the Population: Intention-to-treat (ITT) (primary analysis) and Per-protocol (sensitivity analysis) Descriptive Statistics: Continuous variables: mean ± SD or median (IQR) and Categorical variables: n (%)

Primary Outcome Analysis:

Comparison of cumulative MME at 48 h: If normally distributed → Student's t-test; If non-normal → Mann-Whitney U test Additionally: Linear regression adjusted for: Age, Sex, Surgical technique, Baseline pain Effect size: Mean difference with 95% confidence interval

Secondary Analyses :

Pain scores (repeated measures): Mixed-effects linear models ; Fixed effects: group, time, group × time interaction; Random intercept for patient

Time-to-event outcomes:

Time to first opioid: Kaplan-Meier analysis; Log-rank test; Cox proportional hazards model

Categorical outcomes:

Chi-square or Fisher's exact test; Report relative risks with 95% CI

Continuous outcomes:

t-test or Mann-Whitney depending on distribution Handling Missing Data : Multiple imputation if >5% missing; Sensitivity analyses Significance Threshold : p < 0.05 (two-sided) Randomization Randomization and Blinding : Allocation ratio: 1:1; Computer-generated random sequence with variable block sizes; Allocation concealment via secure electronic system

Blinding:

The patients are blinded; Outcome assessors: blinded; Data analysts: blinded; Performing anesthesiologist: not blinded Data Collection Methods: Pain opiates consumption and functional outcomes will be assessed at predefined time points using scales and validated questionnaires: NRS pain score at rest and during movement, .Lickert scale for patient satisfaction, consumption of rescue analgesia opiates (MME), Brief Pain Inventory and QOR 15 form. Data will be collected during follow-up visits or via structured interviews.

Tipo di studio

Interventistico

Iscrizione (Stimato)

140

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria

  • Adults aged 18 years or older.
  • Scheduled for elective hemorrhoidectomy.
  • Hemorrhoidectomy performed using either the Milligan-Morgan or Ferguson technique.
  • ASA Physical Status I-III.
  • Able to understand the study procedures and provide written informed consent.
  • Able to complete postoperative pain and quality-of-recovery assessments.

Exclusion Criteria

  • Chronic opioid use exceeding 30 mg morphine milligram equivalents per day.
  • Known allergy or contraindication to local anesthetics.
  • Coagulopathy or other contraindication to peripheral nerve block.
  • Infection at the planned injection site.
  • Pregnancy.
  • Cognitive impairment preventing reliable completion of study questionnaires or pain assessments.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Transgluteal pudendal nerve block
Ultrasound-guided bilateral transgluteal pudendal nerve block performed at the level of the ischial spine before pudendal nerve division.
Participants will receive bilateral ultrasound-guided posterior transgluteal pudendal nerve blocks under standardized general anesthesia. With the patient prone or in lateral decubitus, the gluteal region will be prepared aseptically. Ultrasound and color Doppler will identify the ischial spine, sacrospinous and sacrotuberous ligaments, and internal pudendal artery. An in-plane needle will be advanced into the interligamentous target plane, followed by injection of 5 mL ropivacaine 0.5% on each side. Local anesthetic spread will be assessed sonographically. Postoperative analgesia will include paracetamol and celecoxib when appropriate, with rescue opioids given for NRS pain >3/10. Opioid consumption will be converted to morphine milligram equivalents (MME) for analysis.
Comparatore attivo: Transperineal Pudendal Nerve Block
Ultrasound-guided bilateral transperineal pudendal nerve block performed within the ischiorectal fossa near Alcock's canal.
Participants will receive bilateral ultrasound-guided transperineal pudendal nerve blocks following standardized general anesthesia. In lithotomy position, the perineum will be prepared aseptically. A high-frequency ultrasound probe will identify the relevant anatomical structures and the internal pudendal artery using Color Doppler. An echogenic needle will be advanced under ultrasound guidance into the ischioanal/ischiorectal fossa adjacent to the internal pudendal artery. After aspiration, 8 mL of 0.5% ropivacaine will be injected on each side, with ultrasound assessment of anesthetic spread. Postoperative analgesia will consist of standardized paracetamol and celecoxib. Rescue opioids will be administered for pain >3/10 and converted to morphine milligram equivalents (MME) for analysis.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cumulative post operative opioid consumption at 48 Hours (MME)
Lasso di tempo: Post operative From the end of surgery to 48 hours after surgery
Cumulative opioid consumption from the end of surgery through 48 hours after surgery, expressed as morphine milligram equivalents (MME). All postoperative opioid analgesics administered during the observation period will be converted to MME using the prespecified opioid conversion table.
Post operative From the end of surgery to 48 hours after surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
post operative pain intensity at rest
Lasso di tempo: post operative at 2 hours, 6 hours, 12 hours, 24 hours and 48 hours after end of surgery
Pain intensity at rest measured by Visual Analogic Scale (VAS) ruller.
post operative at 2 hours, 6 hours, 12 hours, 24 hours and 48 hours after end of surgery
Post operative pain intensity during defecation
Lasso di tempo: at the first post operative defecation and during the first 48 hours post operative observation period.
Pain Intensity during defecation using Visual Analogic Scale (VAS) ruler
at the first post operative defecation and during the first 48 hours post operative observation period.
Pain Intensity-time area under the curve over 48 hours after the end of surgery
Lasso di tempo: from end of the surgery to 48 hours after surgery
Area under the curve of post operative VAS pain scores from end of the surgery through 48 hours.
from end of the surgery to 48 hours after surgery
cumulative post operative opioid consumption at 12 hours, 24 hours and 36 Hours
Lasso di tempo: Post operative : at 12 hours, 24 hours and 36 Hours after the surgery
cumulative post operative opioid consumption at 12 hours, 24 hours and 36 Hours expressed as morphine miligram equivalents (MME)
Post operative : at 12 hours, 24 hours and 36 Hours after the surgery
Time to first rescue opioid administration
Lasso di tempo: Post operative : from end of surgery through 48 hours after surgery
Time from end of surgery to the first rescue opioid administration
Post operative : from end of surgery through 48 hours after surgery
Proportion of participants who remain opioid free at 48 hours
Lasso di tempo: post operative : From end of surgery through 48 hours after surgery
Proportion of participants who remain opioid free at 48 hours
post operative : From end of surgery through 48 hours after surgery
Quatilty of recovery assessed using the score QoR-15
Lasso di tempo: Post operative : 24 hours and 48 hours after the end of surgery
Post operative Quatilty of recovery assessed using the score QoR-15
Post operative : 24 hours and 48 hours after the end of surgery
Adverse events (Nausea Vomiting Urinary retention)
Lasso di tempo: Post operative : from end of surgery through 48 hours after surgery
Adverse events (Nausea Vomiting Urinary retention) from end of surgery through 48 hours after surgery
Post operative : from end of surgery through 48 hours after surgery
Block related complications
Lasso di tempo: From block performance through 48 hours after surgery
Occurence of complications related to pudendal nerve block
From block performance through 48 hours after surgery
Length of hospital stay after surgery performed
Lasso di tempo: duration of post operative hospitalization : From end of surgery to hospital discharge up to one week
Length of hospital stay from end of surgery to hospital discharge
duration of post operative hospitalization : From end of surgery to hospital discharge up to one week

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 settembre 2026

Completamento primario (Stimato)

31 agosto 2027

Completamento dello studio (Stimato)

30 settembre 2027

Date di iscrizione allo studio

Primo inviato

17 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

7 settembre 2026

Primo Inserito (Effettivo)

10 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

7 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • PINPOINT-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Periodo di condivisione IPD

Beginning 2 months and ending 3 years after the publication of results")

Criteri di accesso alla condivisione IPD

Gross data and statistical analysis will be shared on demand

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .